J Julie Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2315302/publications.pdf

Version: 2024-02-01

	279798	175258
3,067	23	52
citations	h-index	g-index
60	60	2742
60	60	3742
docs citations	times ranked	citing authors
	3,067 citations 60 docs citations	3,067 23 citations h-index 60 60

#	Article	IF	CITATIONS
1	Progesterone Action in Endometrial Cancer, Endometriosis, Uterine Fibroids, and Breast Cancer. Endocrine Reviews, 2013, 34, 130-162.	20.1	378
2	Progesterone resistance in endometriosis: Link to failure to metabolize estradiol. Molecular and Cellular Endocrinology, 2006, 248, 94-103.	3.2	337
3	A microfluidic culture model of the human reproductive tract and 28-day menstrual cycle. Nature Communications, 2017, 8, 14584.	12.8	327
4	Altered expression of HOXA10 in endometriosis: potential role in decidualization. Molecular Human Reproduction, 2007, 13, 323-332.	2.8	208
5	Endometrial receptivity in the eutopic endometrium of women with endometriosis: it is affected, and let me show you why. Fertility and Sterility, 2017, 108, 19-27.	1.0	192
6	Transcriptional Cross Talk between the Forkhead Transcription Factor Forkhead Box O1A and the Progesterone Receptor Coordinates Cell Cycle Regulation and Differentiation in Human Endometrial Stromal Cells. Molecular Endocrinology, 2007, 21, 2334-2349.	3.7	189
7	Role of Progesterone in Endometrial Cancer. Seminars in Reproductive Medicine, 2010, 28, 081-090.	1.1	165
8	The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Molecular and Cellular Endocrinology, 2012, 358, 223-231.	3.2	141
9	Increased Activation of the PI3K/AKT Pathway Compromises Decidualization of Stromal Cells from Endometriosis. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E35-E43.	3.6	122
10	Progesterone Receptor Regulates Bcl-2 Gene Expression through Direct Binding to Its Promoter Region in Uterine Leiomyoma Cells. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4459-4466.	3.6	79
11	CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. Journal of Experimental Medicine, 2017, 214, 2715-2732.	8.5	67
12	Scaffold-Free Endometrial Organoids Respond to Excess Androgens Associated With Polycystic Ovarian Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 769-780.	3.6	60
13	Development of a novel human recellularized endometrium that responds to a 28-day hormone treatmentâ€. Biology of Reproduction, 2017, 96, 971-981.	2.7	51
14	Increased AKT or MEK1/2 Activity Influences Progesterone Receptor Levels and Localization in Endometriosis. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1871-E1879.	3.6	49
15	Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin. PLoS ONE, 2012, 7, e41593.	2.5	45
16	Perinucleolar compartment prevalence is a phenotypic pancancer marker of malignancy. Cancer, 2008, 113, 861-869.	4.1	43
17	Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma. Journal of Hematology and Oncology, 2016, 9, 92.	17.0	40
18	Influence of AKT on Progesterone Action in Endometrial Diseases. Biology of Reproduction, 2014, 91, 63-63.	2.7	35

#	Article	IF	CITATIONS
19	Human fallopian tube epithelium co-culture with murine ovarian follicles reveals crosstalk in the reproductive cycle. Molecular Human Reproduction, 2016, 22, 756-767.	2.8	32
20	Novel Three Dimensional Human Endocervix Cultures Respond to 28-Day Hormone Treatment. Endocrinology, 2015, 156, 1602-1609.	2.8	29
21	Three-dimensional modeling of the human fallopian tube fimbriae. Gynecologic Oncology, 2015, 136, 348-354.	1.4	28
22	HMGA2-mediated tumorigenesis through angiogenesis in leiomyoma. Fertility and Sterility, 2020, 114, 1085-1096.	1.0	27
23	Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells. Journal of Biological Chemistry, 2017, 292, 2237-2254.	3.4	26
24	Microphysiological modeling of the reproductive tract: A fertile endeavor. Experimental Biology and Medicine, 2014, 239, 1192-1202.	2.4	25
25	Exposure of human fallopian tube epithelium to elevated testosterone results in alteration of cilia gene expression and beating. Human Reproduction, 2020, 35, 2086-2096.	0.9	25
26	Establishment of Human Patient-Derived Endometrial Cancer Xenografts in NOD scid Gamma Mice for the Study of Invasion and Metastasis. PLoS ONE, 2014, 9, e116064.	2. 5	25
27	Dysfunctional MnSOD leads to redox dysregulation and activation of prosurvival AKT signaling in uterine leiomyomas. Science Advances, 2016, 2, e1601132.	10.3	24
28	Oxidative stress-induced miRNAs modulate AKT signaling and promote cellular senescence in uterine leiomyoma. Journal of Molecular Medicine, 2018, 96, 1095-1106.	3.9	23
29	Comparative analysis of <i>AKT</i> and the related biomarkers in uterine leiomyomas with <i>MED12, HMGA2</i> , and <i>FH</i> mutations. Genes Chromosomes and Cancer, 2018, 57, 485-494.	2.8	21
30	The allosteric AKT inhibitor, MK2206, decreases tumor growth and invasion in patient derived xenografts of endometrial cancer. Cancer Biology and Therapy, 2017, 18, 958-964.	3.4	20
31	Generation of Multicellular Human Primary Endometrial Organoids. Journal of Visualized Experiments, 2019, , .	0.3	19
32	Microphysiological Modeling of the Human Endometrium. Tissue Engineering - Part A, 2020, 26, 759-768.	3.1	19
33	Fenretinide: A Potential Treatment for Endometriosis. Reproductive Sciences, 2016, 23, 1139-1147.	2.5	15
34	Microphysiologic systems in female reproductive biology. Experimental Biology and Medicine, 2017, 242, 1690-1700.	2.4	15
35	BRCA1 mutation influences progesterone response in human benign mammary organoids. Breast Cancer Research, 2019, 21, 124.	5.0	15
36	The AKT/BCL-2 Axis Mediates Survival of Uterine Leiomyoma in a Novel 3D Spheroid Model. Endocrinology, 2018, 159, 1453-1462.	2.8	14

#	Article	IF	CITATIONS
37	Application of ex-vivo spheroid model system for the analysis of senescence and senolytic phenotypes in uterine leiomyoma. Laboratory Investigation, 2018, 98, 1575-1587.	3.7	14
38	Synuclein- \hat{I}^3 (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease. Journal of Ovarian Research, 2016, 9, 75.	3.0	13
39	Mechanism of Telapristone Acetate (CDB4124) on Progesterone Receptor Action in Breast Cancer Cells. Endocrinology, 2018, 159, 3581-3595.	2.8	13
40	Progesterone receptor blockade in human breast cancer cells decreases cell cycle progression through G2/M by repressing G2/M genes. BMC Cancer, 2016, 16, 326.	2.6	12
41	Paracrine Pathways in Uterine Leiomyoma Stem Cells Involve Insulinlike Growth Factor 2 and Insulin Receptor A. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1588-1595.	3.6	11
42	Synucleinâ€Î³ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer, 2017, 123, 1144-1155.	4.1	11
43	Transcriptional Profiling of Human Endocervical Tissues Reveals Distinct Gene Expression in the Follicular and Luteal Phases of the Menstrual Cycle1. Biology of Reproduction, 2016, 94, 138.	2.7	10
44	Reply: Exposure of human fallopian tube epithelium to elevated testosterone results in alteration of cilia gene expression and beating. Human Reproduction, 2021, 36, 1725-1725.	0.9	10
45	Association of body mass index with ER, PR and 14-3-3Ïf expression in tumor and stroma of type I and type II endometrial carcinoma. Oncotarget, 2017, 8, 42548-42559.	1.8	9
46	Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland. Breast Cancer Research, 2021, 23, 78.	5.0	7
47	A small molecule inhibitor of the perinucleolar compartment, ML246, attenuates growth and spread of ovarian cancer. Gynecologic Oncology Research and Practice, 2018, 5, 7.	3.6	6
48	Hormonal strategies in gynecologic cancer: Bridging biology and therapy. Gynecologic Oncology, 2018, 150, 207-210.	1.4	5
49	Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes. Cancer Letters, 2021, 520, 255-266.	7.2	5
50	Disparities in gynecologic cancer incidence, treatment, and survival: a narrative review of outcomes among black and white women in the United States. International Journal of Gynecological Cancer, 2022, 32, 931-938.	2.5	5
51	Mentorship 2.0. Endocrinology, 2018, 159, 2361-2362.	2.8	2
52	Preparing for implantation. ELife, 2021, 10, .	6.0	2
53	Establishment of breast tumor spheroids: An emerging research tool. Molecular Reproduction and Development, 2018, 85, 174-174.	2.0	0
54	Abstract PS19-09: Alternative splicing events from progesterone exposure differ based on BRCA1 mutation status. , 2021 , , .		0

#	Article	IF	CITATIONS
55	Î ³ -synuclein expression in ovarian cancer Journal of Clinical Oncology, 2013, 31, 5574-5574.	1.6	O
56	Efficacy of metarrestin against ovarian cancer Journal of Clinical Oncology, 2015, 33, e16573-e16573.	1.6	0